Drug intelligence / Profile preview

GSKVX000000070248

Development stage: Phase 1
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics

Overview

GSKVX000000070248 is an undisclosed GSK investigational vaccine-related active substance identifier. It is listed as an investigational product in GSK's Phase 2a study 300336 of mRNA-based multivalent seasonal influenza vaccine candidates in adults. Publicly available trial information does not disclose the molecular structure, encoded antigen, influenza strain composition, or a distinct mechanism attributable specifically to GSKVX000000070248; therefore, it should not be conflated with the overall multivalent vaccine formulations studied in the trial. ([gsk-studyregister.com](https://www.gsk-studyregister.com/trials/300336))

Other names: FLU-Q-PAN H7N9

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on GSKVX000000070248.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSKVX000000070248.

Explore the full profile